导师风采
返回
李彦欣
研究员
博士生博导
科室：转化所
专业：肿瘤学
上海儿童医学中心血液肿瘤科血液重点实验室研究员
个人简介
李彦欣，女，73.6.23出生，儿童血液以及实体肿瘤增殖和干性维持的分子机制。2004年毕业于中国农业大学生物学院获得理学博士学位，2007-2012年在美国匹兹堡大学医学院放射医疗系做博士后，2013年在上海儿童医学中心聘为副研究员，2019年聘为研究员。曾获得浦江人才计划资助。建立并完善了无插入的体细胞重编程平台和向神经，心肌，造血细胞等的分化平台，申请并获得国家发明专利3项。本人并以实体瘤为研究对象，对肿瘤发生发展及肿瘤干细胞干性维持机制进行了深入研究。近年以通讯或一作在blood（2021）、Signal Transduction and Targeted Therapy （2021）、Nature Communications（2013，2017，2019）、EMBO Reports (2019)、Neuro-Oncology （2015，2019）等国际著名生物医学杂志发表SCI论文40余篇。研究得到国家自然科学基金-面上、上海市科委、上海市浦东新区等基金的支持。担任International Society for Stem Cell Research等会员，担任 Frontiers in Enthopharmacology评审专家等。曾获天津市自然科学一等奖、高等学校科学研究优秀成果奖。
研究方向
细胞治疗在血液肿瘤中的应用研究；
招生信息
| 序号 | 专业 | 招生类型 | 招生人数 | 年份 |
| 1 | 肿瘤学 | 学术型硕士 | 1 | 2022 |
| 2 | 肿瘤学 | 学术型博士 | 1 | 2024 |
科研项目
1. 国家自然科学基金，81972341，TRIM24在MYCN调控的高危儿童神经母细胞瘤增殖中的作用及机制，2020-01至2023-12， 55万，在研，主持
2. 国家自然科学基金，81772663，泛素连接酶TRIM59调控胶质瘤发生发展的分子机制，2018-01至2021-12， 55万，在研，主持
3. 国家自然科学基金，81470315，利用iPS技术研究复发T-细胞急性淋巴细胞白血病（T-ALL）细胞亚克隆中基因变异特征及其耐药复发机制，2015-01 至2018-12，70万，完成，主持
4. 国家自然科学基金重点项目, 81330015, 骨髓衰竭的病理机制及干预策略的基础研究, 2014-01至2018-12， 290万，完成，参与
5. 重大慢性非传染性疾病防控研究，2018YFC1313005，高危神经母细胞瘤发生、复发及转移的分子基础研究，2018-01至2020-12， 180万，在研，参与
6. 上海市科学技术委员会，201409002700，神经干细胞恶性转化为胶质瘤的动物模型构建研究，2020-6至2023-6，20万，在研，主持
7. 浦东新区科技发展基金，PKJ2018-Y47，核酸代谢合成酶PRPS2在伯基特淋巴瘤发生、发展以及治疗中的分子机制研究，2018-12至2021-12,10万，在研，主持
8. 交大医工（理）交叉，YG2017MS32，泛素连接酶在肿瘤及肿瘤干细胞中的作用，2018-1至2020-12,21万，完成，主持
9. 2014年获得上海浦江人才计划支持，14PJ1406500，利用iPSC 技术研究复发急性淋巴细胞白血病（T-ALL）细胞亚克隆中基因变异特征及其耐药复发机制，2014-07至2016-06, 20万,完成，主持
研究成果
1. Ting Li#, Yingwen Zhang#, Yang Li#, Xiang Wang, Weiqiao Bao, Jun Huang, Yani Ma, Shanshan Li, Siqi wang, Yi Yang, Yanfeng Liu*, Yijin, Gao*, Haizhong Feng*, Yanxin Li*. Modeling leukemia with pediatric acute leukemia patient-derived iPSCs. Stem cell research 2021, May 25;54: 102404. doi:10.1016/j.scr.2021.102404.
2. Wenxue Liu#, Zhiyan Zhan#, Meiying Zhang#, Bowen Sun, Qiqi Shi, Fei Luo, Mingda Zhang, Weiwei Zhang, Yanli Hou, Xiuying Xiao, Yanxin Li *and Haizhong Feng*. KAT6A, a novel regulator of β-catenin, promotes tumorigenicity and chemoresistance in ovarian cancer by acetylating COP1. Theranostics 2021 April, Vol. 11, Issue 13, 6278-6292.
3. Jin Wook Kang#, Zhiyan Zhan#, Guangzhen Ji#, Youzhou Sang, Daohong Zhou, Yanxin Li*, Haizhong Feng*, and Tao Cheng*. PUMA facilitates EMI1-promoted cytoplasmic Rad51 ubiquitination and inhibits DNA repair in stem and progenitor cells. Signal Transduction and Targeted Therapy 2021 Mar 31;6(1):129. https://doi.org/10.1038/s41392-021-00510-w.
4. Yi Yang#, Lili Song#, Xia Huang#, Yanan Feng#, Yingwen Zhang, Yanfeng Liu, Shanshan Li, Zhiyan Zhan, Liang Zheng*, Haizhong Feng*, and Yanxin Li*. PRPS1-mediated purine biosynthesis is critical for pluripotent stem cell survival and stemness. Aging-US, January 20, 2021, 13(3), 4063-4078.
5. Lili Song#, Bo Yu#, Yi Yang, Jianwei Liang, Yingwen Zhang, Lixia Ding, Tianyi Wang, Xinyu Wan, Xiaomin Yang, Jingyan Tang, Shengyue Wang*, Benshang Li*, Yanxin Li*, Haizhong Feng*. Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia. Blood. 2021 Mar 4;137(9):1181-1191. doi: 10.1182/blood.2020005622.
6. Yang Li#, Ting Li#, Yuejia Tang#, Zhiyan Zhan, Lixia Ding, Lili Song, Tingting Yu, Yi Yang, Jing Ma, Yingwen Zhang, Ying Zhou, Song Gu, Min Xu*, Yijin Gao*, Yanxin Li*. The function of a heterozygous p53 mutation in a Li-Fraumeni syndrome patient. Plos one 2020 Jun 9; 15(6):e0234262. doi: 10.1371/journal.pone.0234262.
7. Ting Li#, Lili Song#, Yingwen Zhang#, Yali Han#, Zhiyan Zhan, Zhou Xv, Yang Li, Yuejia Tang, Yi Yang, Siqi Wang, Shanshan Li, Liang Zheng*, Yanxin Li*, Yijin Gao*. Molecular mechanism of c-Myc and PRPS1/2 against thiopurine resistance in Burkitt's lymphoma. Journal of cellular and molecular medicine. 2020 May. 24(12):6704-6715. doi: 10.1111/jcmm.15322.
8. Jianming Tang#, Bo Yu#, Yanxin Li#, Weiwei Zhang, Angel A Alvarez, Bo Hu, Shi‐Yuan Cheng, Haizhong Feng*. TGF‐β‐activated lncRNA LINC00115 is a critical regulator of glioma stem‐like cell tumorigenicity. EMBO Rep 2019 Dec 5; 20(12):e48170. doi: 10.15252/embr.201948170.
9. Youzhou Sang#, Yanxin Li#, Yingwen Zhang, Angel A. Alvarez, Bo Yu, Weiwei Zhang, Bo Hu, Shi-Yuan Cheng, and Haizhong Feng*. CDK5-dependent phosphorylation and nuclear translocation of TRIM59 promotes macroH2A1 ubiquitination and tumorigenicity. Nature Communications 2019 Sep 5; 10(1):4013. doi: 10.1038/s41467-019-12001-2.
10. Youzhou Sang#, Yanli Hou#, Rongrong Cheng, Liang Zheng, Angel A. Alvarez, Bo Hu, Shi-Yuan Cheng, Weiwei Zhang*, Yanxin Li*, and Haizhong Feng*. Targeting PDGFRa-activated Glioblastoma through Specific Inhibition of SHP-2-mediated Signaling. Neuro-Oncology. 2019 Nov 4;21(11):1423-1435
11. Zhiyan Zhan#, Lili Song#, Weiwei Zhang#, Haihui Gu, Haizi Cheng, Yingwen Zhang, Yi Yang, Guangzhen Ji, Haizhong Feng*, Tao Cheng*, and Yanxin Li*. Absence of cyclin-dependent kinase inhibitor p27 or p18 increases efficiency of iPSC generation without induction of iPSC genomic instability. Cell Death & Disease 2019 Mar 20;10(4):271. doi: 10.1038/s41419-019-1502-8.
12. Yinfang Wang#, Yanli Hou, Weiwei Zhang, Angel A. Alvarez, Yongrui Bai, Bo Hu, Shi-Yuan Cheng, Kun Yang*, Yanxin Li*, and Haizhong Feng*. Lipolytic inhibitor G0S2 modulates glioma stem-like cell radiation response. Journal of Experimental & Clinical Cancer Research April 5, 2019, 38(1):147. doi: 10.1186/s13046-019-1151-x.
13. Cai Jiaoyang#, Huang Xia#, Yin Minzhi#, Pan Ci, Song Lili; Zhan Zhiyan, Chen Jing, Gao Yijin, Tang Jingyan, Li Yanxin*, Shen Shuhong*. A novel fusion gene PLEKHA6-NTRK3 in langerhans cell histiocytosis. International Journal of Cancer 2019 Jan; 144(1):117-124.
14. Haihui Gu#, Xia Huang#, Jing Xu#, Lili Song, Shuping Liu, Xiao-Bing Zhang, Weiping Yuan, Yanxin Li*. Optimizing the method of generation of integration-free iPS cells from human peripheral blood. Stem Cell Research & Therapy. 2018 Jun; 9(1):163.
15. Jianming Tang#, Yanxin Li*, Youzhou Sang, Bo Yu, Deguan Lv, Weiwei Zhang, and Haizhong Feng*. LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling. Oncogene 2018 May; 37(34):4723-4734.
16. Youzhou Sang#, Yanxin Li*#, Lina Song#, Angel A. Alvarez#, Weiwei Zhang, Deguan Lv, Jianming Tang, Feng Liu, Zhijie Chang, Shigetsugu Hatakeyama, Bo Hu, Shi-Yuan Cheng, and Haizhong Feng*. TRIM59 promotes gliomagenesis by inhibiting TC45 dephosphorylation of STAT3. Cancer Res 2018 April; 78(7):1792-1804.
17. Deguan Lv#, Feng Jia#, Yanli Hou#, Youzhou Sang, Angel A. Alvarez,Weiwei Zhang, Wei-Qiang Gao, Bo Hu, Shi-Yuan Cheng, Jianwei Ge*, Yanxin Li,* and Haizhong Feng*. Histone Acetyltransferase KAT6A upregulates PI3K/AKT signaling through TRIM24 binding. Cancer Research 2017 Nov; 77(22):6190-6201.
18. Deguan Lv#, Yanxin Li#, Weiwei Zhang, Angel A. Alvarez, Lina. Song, Jianming Tang, Wei-Qiang Gao, Bo Hu, Shi-Yuan Cheng, Haizhong Feng*. TRIM24 is an oncogenic transcriptional co-activator of STAT3 in glioblastoma. Nat Commun. 2017 Nov; 8: 1454.
19. Xia Huang#, Lili Song#, Zhiyan Zhan#, Haihui Gu, Haizhong Feng*, and Yanxin Li*. Factors affecting mouse somatic cell nuclear reprogramming by rabbit ooplasms. Cellular Reprogramming. 2017 Dec 19(6):344-353.
20. Lei Zhang#, Weiwei Zhang# , Yanxin Li #, Angel Alvarez，Zuoqing Li, Yinfang Wang，Lina Song，Deguan Lv，Ichiro Nakano，Bo Hu，Shi-Yuan Cheng, Haizhong Feng*. SHP-2 upregulated ZEB1 is important for PDGFR alpha driven glioma epithelial-mesenchymal transition and invasion in mice and humans，Oncogene, 2016 April ; 35:5641–5652.
